Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 401787
Title Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge
Author(s) Boer, S.M. de; Kortekaas, J.A.; Antonis, A.F.G.; Kant, J.; Oploo, J.L. van; Rottier, P.J.M.
Source Vaccine 28 (2010)11. - ISSN 0264-410X - p. 2330 - 2339.
DOI http://dx.doi.org/10.1016/j.vaccine.2009.12.062
Department(s) CVI - Division Virology
CVI Virology
Publication type Refereed Article in a scientific journal
Publication year 2010
Keyword(s) envelope glycoproteins - immunogenic properties - monoclonal-antibodies - immune-responses - hantaan-virus - particles - expression - adjuvants - proteins - segment
Abstract Rift Valley fever virus (RVFV) is an emerging mosquito-borne virus causing significant morbidity and mortality in livestock and humans. Rift Valley fever is endemic in Africa, but also outside this continent outbreaks have been reported. Here we report the evaluation of two vaccine candidates based on the viral Gn and Gc envelope glycoproteins, both produced in a Drosophila insect cell expression system. Virus-like particles (VLPs) were generated by merely expressing the Gn and Gc glycoproteins. In addition, a soluble form of the Gn ectodomain was expressed and affinity-purified from the insect cell culture supernatant. Both vaccine candidates fully protected mice from a lethal challenge with RVFV. Importantly, absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocapsid protein-based indirect ELISA.
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.